04:54 AM EDT, 08/21/2026 (MT Newswires) -- Genetic Analysis AS (GEAN.OL) said Friday it launched its microbiome testing technology at the Centre for Digestive Diseases in Sydney, Australia, the company's first deployment in the country. The molecular diagnostics company's GA-map Dysbiosis Test is a clinically validated test designed to characterize deviations in gut microbiota, supporting diagnosis and management of patients with gastrointestinal disorders and microbiome-related conditions. The Australian launch is in line with the company's global expansion strategy.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.